Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.

The conversation discusses using shou wu chih or fo-ti/he shou wu for hair loss, with OP noticing stiffer beard and body hair. A user warns about potential liver damage from fo-ti and questions the effectiveness of alternative medicine.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

Exploring future hair loss treatments, including immunosuppressants for hair transplants and hair cloning, with a focus on leveraging research from other medical fields. Current treatments like finasteride and minoxidil are effective for most, but there's a call for more funding and innovation in the hair loss industry.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

The conversation discusses hair loss treatments, specifically Regenera stem cells and exosomes from 'Cellgenic' umbilical cord donors. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without seeing effects, and another user mentions the importance of microneedling.

The conversation discusses a hair loss and scalp care routine involving ciclopirox shampoo, benzoyl peroxide, clindamycin gel, clobetasol propionate, and calcipotriol to manage seborrheic dermatitis, folliculitis, and inflammation. It also touches on the role of diet and other treatments like oral minoxidil and pioglitazone for scalp health.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

Sulforaphane, found in broccoli sprouts, promotes hair growth by degrading DHT. Users discuss its potential benefits and joke about unconventional application methods.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.

Rating treatments for hair loss, with the help of GPT-4, according to efficacy, evidence and tolerability; a combination of chemicals from research papers, custom compounds, and some suggestions from other users were included.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.

The conversation discusses the effectiveness of finasteride and microneedling for treating hair loss. The linked article is seen as an advertisement for these treatments.

RU and Pyri block androgen receptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.

The conversation discusses alternative hair growth treatments to minoxidil, including Stemoxydine, Tretinoin, adenosine, Baicalin, castor oil, Latanoprost/bimatoprost, and Redensyl. Users share their experiences and opinions on the efficacy of these treatments.

The conversation discusses the effectiveness of commercial Low-Level Laser Therapy (LLLT) devices for hair growth, suggesting they are underpowered compared to the ideal energy output shown in medical research. A user plans to build a custom helmet that meets the required specifications for effective treatment.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

Researchers finding that microRNA can potentially regrow 90% of lost hair, and the challenges involved in moving this research forward to human trials. Various treatments for hair loss, such as finasteride and minoxidil, have been discussed.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.